Charity registration number 1194608
THE CANCER TREATMENT AND RESEARCH TRUST
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
Sob•ll RI￿d•S LLP
The Kinetic Centre
Theobald Str&•t
Elstree
Borehamwood
Hèrtfordshlr•
WD6 4PJ

THE CANCER TREATMENT AND RESEARCH TRUST
LEGALAND ADMINISTRATIVE INFORMATION
Trustees
Mr Russell Hallam
Dr Paul Nathan
DrA Sharrna
Dr David Pinato
Prof. Mithael Seckl
Prof. Gordon Rusb'n
Ms Kirandeep G￿WaI
Dr Ehsan Ghorani
Mr Glen Williams
Professor Maraa Hall
IAppointed 17 May 20261
IReliremenl 31 July 20251
Charlty number
1194608
Prlnclpal addr•s•
Upper East Research Office
Mount Vemon Hospital
Rickmansworth Rood
Northwc*>J
HA6 2RN
Ind•pgnd•nt •xamln•r
Sobell Rhodes LLP
The Kinétic Cèntrè
Theobald Street
Elslre&
Borehamwocxj
Hertfordshire
Unitèd Kingdom
WD64PJ

THE CANCER TREATMENT AND RESEARCH TRUST
CONTENTS
Page
Trustees report
Statèment of trust885 r8sponsibilitl85
14
Independent examinerfs report
Statement of financial acts'vities
16
Balan¢¢ $hegt
17
Notes to the ffinanual slalements
18-29

THE CANCER TREATMENT AND RESEARCH TRUST
TRUSTEES REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
The tru5t8es hav8 adopted th8 provisions ol Ar£ounting 8nd Rew)rting by Charitle5.' Stat&m8nt of R8cornmended
Practice applicable to charities preparing their accounts in accordance wth the Finanaal Reporting Standard
applicable in the UK and Republic of Ireland IFRS 1021 (effective 1 January 20191.
STRUCTURE. GoveRNANCE, MANAGEMENT
The Cancer Treatrnent and Research Trust ICTRTI which was founded in 1985, supports work mainly in the
d8partm8nt5 of medical oncology at the W8St London Cancer Cenire bas8d at Charing Cr055 and Hammer5mith
Hospitals Ilmperial College Healthcare NHS Trust) and in the department ol medical oncobjy at the ￿Unt Vemon
Cancer Cenlre, in Northwood, Middlesex.
The charity is a Charitsble Incorporated Organisation ICIOI registered Ihe Charity Commission. 11 is govemed
by its constituts¢n, and the irustees are re5ponsibl¢ ftr ensuring compliarbce with thai goveming document.
The lomer unincorporated trust remains on the regisler solèly to manage rèsidual matters arising from the 2022
transition and does not undertake actsve operat￿ns.
Truste•s
Thè eharity is govembd by 3 8oafd of Trusteès comprising individuals with professional baekgrounds in mèdicinè.
law and other relevant disciplines. The Board indudes cancer specialists. reflectin9 the charity's principal objectives
and research activities.
Trustees are appoinied in accordance %•thh Ihe charity's constslution. New ¢nJsiee8 receive an induction covering
thèir lègal duligs, govèmancè proeèssès, and th¢ charity's kèy poliuès.
Trustees are required to dedare and manage any conflicts of interest in line with the charity's confllcts pollcy.
In July 2025, Professor Marc4a Hall stepped down as a truslee of the charrty.
AdmlnlJtrAtlon
On 1st January 2022, CTRT offiaally transitioned to a Charilable Ino)rporated Organisalion ICIOI status. The
original Can￿r T￿atment and Research Trusl (charity number 2929091 remains registered as a charity with the
Charity Commission. albeit it only remains aclive in order to manage any ￿sIdUal matters following the 2022
Ir8nsitio)n.
Charfty Manag•r
The Charity Manager is ￿spOnsible for Ihe day-lcrday cyeration ol ihe charity and manages its staff on behalf ol
the Iruslees.
Mrs Laura Brown has h8ld this positron srncè Junè 2021. During 2025. Mrs Fiankiè Brittan join8d th8 charity on a
temporary basis to provi¢Je cover during Mrs Brown's per¥)d of leave.
ObJ8ctlves and acllvltles
The Cancer Treatment and Research Trust ICTRTI which was founded in 1985. supports work mainly In the
departments of medical oncology at the West London Cancer Centre based at Charing Cross Hospital and in the
department ol medical oncology al Ihe Mount Vernon Cancer Centre. in Northwood. Middlesex. The CTRT exists lo
support treatment and research into many foThs of malignant disease and has been particularfy involved in
understanding how Certain cancers dev8k)p, finding better ways to monitor them and developing new anti-cancgr
agents. It remains committed to lunding r85earch that is rK>t Èd8qU8tely funded eith8r by th8 tnajor oncer charities
such as CRUK, the MRC or the phamaceutical industry.

THE CANCER TREATMENT AND RESEARCH TRUST
TRUSTEES REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
The r8S88rch support8d by CTRT can ￿ rO￿￿lY 5pif( into th8 following ar88S'.
Ovarian, uterine and rafe gynaecological cancers
Lung Cancer
Tests'cular and Ovarian Germ Cell Cancer
Gestational Trophoblastic Di5ea5e
M81anorna
Renal Cancer
Immunotherapyllmmunology
Novel Therapies
The trustees confimi that they have had due regard to the Charity Commission's guKlance on public benefrt when
reviewing th8 charity's 8irn$. obiocbvos and actiwties.
Aehlov•m•nt8 and ￿rtornIaneé
Significant 8CtAVItAes 8nd 8¢1Jiev8ments against obigctiv8$
The trustees are pleased with the achievements and perfomiance of the Trust in 2025.
In 2025, r8sèareh, either fully or partly lund8d by CTRT. l•d lo 73 publication$.
This included research which..
Led lo the first set ol glob81 consensus-ba5ed Irealmenl guidelines for GTD
Updaied UK guidelines lor the manag¢moni of uv$al m*lanoma
Evaluated clinical outcomès in patiènts wilh mètastatic hom)on• sènsitlV8 proslalè cancar tr88t•d with
triplet therapy (Darolutamide in combinalion with docetsxel chemotherapy and androgen deprivation
therapy based on ARASENS trial resultsl Ilhe RECOMMEND study)
Provided evidence from an expanded mvlti-centre lrial (phase 111 TOPAZ-11 which supports the adoption of
durvalumab18n immunolher8Py treatment) in combin81ion wlh gerncilabine and cispl81in in routine dinic81
praciieè lor palianls wilh advancèd ￿liary tract cancar.
A lull list ol the pu￿1Shed papers is below..
Vengalil S. Mohammed R, Das P, Sharrn8 A.
V*ngalil K, Wickrarnasinghe K. Reid l R, Lim J H. Septèmbèr 2025. Annals of Onc01￿3Y 36.. S1293
DOI". 10.101611.annonc.2025.08.2993.
Amaral T, Nanz L, Hi9uiia LMS, Ascierto P, B8rking C, Cou5elo EM, Donia M, Durnrn8r R, GutZrn8r R,
Haushild A, Jalving M, Loe R. Lorigan P, Maiquez-Rodas I, Michelin O. Nathan P, Rtsbèrt C, Sch8dendorf
D, Sobczuk P, FlaQ L, Leiter U. Ga￿ C. Eur J CatKer. 2025 Jan 17,'215.
Singal AG, Salem R. Pinaio OJ, Pillai A. Gaslroenlerology. 2025 Sep'169141'.585-599. dim.. 10.10531
j.gastro.2025.03.047. Epub 2025 May 2. PMID.- 40320088.
win
J Hepatocell Carcinorna. Stef8r)ini B. Fulgenzi CAM, Scheiner B, Korolewicz J, Cheon J, Nishida N, Ang C.
Marron TU, Wu YL, S8eed A, Wi8tham B. Rim8ssa L, Pirozzi A, Carnrnarota A, Pressiani T, Pinter M,
Balcar L, Huang YH, Mehan A, Phen S, Vwaldi C, Salani F. Masi G, 8eth.nger D, Vogel A, Schanlein M, von
Felden J, Schulze K, Wege H, Samson A, Galle PR, Kudo M, Manf￿1 GF, Celsa C, Awosika N, Cortellini
A, Singal AG. Sharma R. Chon HJ. Tovoli F. Piscaglia F. Pinato DJ. DAessio A. 2025 Apr 4'.12.'671-683.
doi.. 10.21471JHC.S462701. PMID.. 40201222.. PMCID.. PMC11977629.

THE CANCER TREATMENT AND RESEARCH TRUST
TRUSTEES REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
A hase 1b mutticentre d05e e5fdlation safe
and hafrnacokinetscs stud ol tilvestarnab
BG8149
la
sed I tinum-resi
rade sertsu
ovarian
ncer
PROC
alienl Sooi K, Tan TZ, Kim JW,
Lee JY, Kim BG, Micklem D. Jackson A. Pinato DJ, Goutley C, Kristeleit R. Blagden SP, Bjorge L, Tan DSP
Br J Cancer. 2025 Ocl..133161'.89&908. doi.. 10.10381s41416-025-03090-6. Epub 2025 Jul 22. PMID..
40696160: PMCID.. PMC12449448.
Celsa C. Pinato DJ. Cabibbo G. J Hepatol. 2026 Feb.'84121-'e77-e79. 10.1016tI.jhep.2025.10.009. Epub
2025 Oct 17. PMID.. 41110521.
Ghidini M. Hahne JC. Senli C. Heide T. Proszek PZ. Shaikh R. Carter P. Hubank M. Trevisani F, Garrone O.
Cappelle¢ti MR. Generali D, Cattaneo M. Gnocchi N. Donats G. Gobbi A. Grizzi G. Lampis A, El9hadi R,
Tanzi G, Tornasello G, Ratti M, Pina¢o DJ, Fassan M. Vlachogiannis G. Sottoriva A, Cortellini A,
P8S58lacqua R, Val8ri N. Clin
Cancèr Res. 2025 Fab 17,"31141..707-718. doi." 10.11S8I10784￿32.CCR-24-O924. PMID.. 39688961.
Seckl MJ, Kaur B. Ghorani E. Bergamini A. Mangili G. Int J Gynecol Cancer. 2025 M8r,'35131'.101670. doi..
10.10161j.ijgc.2025.101670. Epub 2025 Jan 29. PMID.. 40020416.
Vitale A, Kim JS, Cabibbo G. Casadei-Gardini A. lavarone M. Rimassa L.
Ponziani FR, Tovoli F, Chon HJ, Kang B, Kim C. Imaoka H. Ikeda M. Kudo M. Aoki
T. Tortora R. Guarracino M. Slelanini B, Marseglia M. SparacinoA. Celsa C,
Bruccoleri M. Alimen¢i E. Marra F, Camp8ni C. Bhoori S. Mazzaferro V. Sacco R,
Facciorusso A, Martini A, Stella L. Cerrilo L. Toyc¥Ya H. Yasud8 S, Rossari F,
Rimini M, Suda G, Sho T, Masi G, Vivaldi C, Prèssiani T, Kakizaki S, N89anuma A,
Avallone A, Nappi A. Vidili G, SoldA c. B&rgamo F. Pinato DJ. Pelizzaro F.
Foschi FG, Secomandi A, Verderame F. Bronte E, Math'nelli E. Marino D. Grasselli
S. Olivani A. Brunello MR. Damone F. Mega A. Marzi L. Tamburini E. Ramundo M,
Federico P, Daniele B. Giannini EG. Pasla A. Morisco F. Guarino M. Hoyek C.
Boninsegna S, Gupt8 A, Sacerdoti D, Oalbeni A. Calvo Ram¢)s I, Adev8 J, Saitta C.
Pitronè C. L6ntJni Graziano ML, Farèlla N, Rendina M, Grassi T. R(xJnqu8nz MG.
Maiello E. Presa J, Pinho l. Hiasa Y. Hirooka M. Chen J. Arrichiello G, Aschele
C, Furlanetto A, Cillo U. Liver Cancer. 2025 Aug 5. doi.. 10.11591(X)0547792. Epub ahead of print. PMID..
41063731; PMCID.. PMC12503878.
vi
S Mehrotra. A C Redla, J K Tan. A Ghose. A Maniam. S Boussios. G L Banna, P Das. S Adeleke, A Sharma,
IUC24417-83 The Oncologist, Volume 30. Issue Supplement 1, September 2025, oyaf248.011, bl(p
ctDNA.. A Gatewa
alO￿llular Cancer
Pinalo DJ, Lombardi P, D'Alessio A, TorkpM)ur A, Fulgenzi CAM, Brunetti L. Clin Cancer Res. 2025 Mar
17',31161.'955-957. doi.. 10.11581107&0432.CCR-24-3805. PMIO.. 39792474.
aliz
trattfirAti n in
nt
l tr h bl ti
Seckl MJ, Ghorani E. Ann Oncol. 2025 Oct,"361101:1111-1112. diN." 10.10161j.annonc.2025.07.018. Erxjb
2025 Aug 6. PMID". 407746(MJ.

THE CANCER TREATMENT AND RESEARCH TRUST
TRUSTEES REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
D88
L88rnln
Mod&l for Predictin
Immunothera
Res
n58 in Adv8nced Non-small C811 Lun
Canc8r
Rakaee M, Tafavvoghi M, Ricaub" 8, AJe5si JV, Cortellini A. Citarella F, Nibid L, Perrone G, Adib E, Fulgenzi
CAM, Hidalgo Filho CM, Di Federico A, Jabar F. Hashemi S, Houda I, Richardsen E, Rasmussen Busund
LT, Donnem T, Bahce I, Pinato DJ, Helland A... Shdl LM, Awad MM. Kwiatkowski DJ. JAMA Oncol. 2025
Feb 1'.11121'.109-118. doi.. 0.10011jamaoncol.2024.5356. PMID.. 39724105.. PMCID.. PMC11843371.Qg2o
r DNA
chernoernbolization in he
atocellular carrinoma
Sharrna R, Alharbi SN, Ellum K, Motedayen-Aval L, Casadel￿ardInl A, Pinato
DJ, Bettinger D, Bengsch 8, Patel R, Evans J. NPJ Prec¢s Oncol. 2025 Jul 1".9111'.214. doi.. 10.10381
s4169&02&00961-2. PMID.. 40596669: PMCID.. PMC12218101.
Savage P, Froeling F, Lythgoe M. Fishèr R, Maher G. Winter M. Erèméishvili K. Sarwar N, Aguiar X, Slngh
K, Hancock B, Coleman R. Tidy J, Seckl MJ.J Obstet Gynaecol. 2025 0&c'.45111.'2571184. dd..
10.1080101443615.2025.2571184. Epub 2025 Oct 16. PMID.. 41099823.
rrnin
rviv
h fi
Cortèllini A, Brunetti L. Di Fazio GR. Garbo E. Pinalo DJ. Nald￿) J. Katz A. Loza M. Near JW, Genova C.
Getlinger S, Kim SY. Jayakrishnan R. El Zarif T. Russano M. Pecci F. Di Federico A. Awa(J M. Alessi JV,
Montrone M. Owen DH. Signorelli D. F￿ler MJ. Li M. Camerini A, De Giglio A. Young L. Vincenzi B, Metro
G, Passiglia F. Yendamuri S, Guida A. Ghidini M. Awosika NO. Napolrtano A. Fulgenzi CAM. Gri58nti S,
Grossi F, D'lncecco A, J¢sephides E, Van Hernelrijck M, Russo A. Gelibter A, Spinelli G, Verrico M. Tom85ik
8, Giusli R, Newsom-Davis T, Bria E. Sebasiian M, Rosl M. Forster M, Mukhèrieè U. Landi L, Mazztsni F,
Aujayeb A, Dupont M, Curioni-Fonlecedro A. Chiari R. Pantano F. Morabito A. Laonetti A. Friedlaender A.
Addeo A, Zorallo F. De Tursi M. Canlini L. Roca E. Mountzios G. Oella Gravara L. Kalvapudi S, Inno 4
Bironzo P. Di Marco Barros R. O'Reilly D. Bell J. Karapanagiotou E. Monnet l. Baena J. Macerelli M, Majern
M, Agusloni F, Cortinovis DL. Tonini G, Minuts G. Bennali C. Mezquits L. GorrAa T. Servelto A,
Benin8to T, Lo Russo G, Rogado J, Moliner L. Biello F. Aboubakar Nana F, Dingernans AM, Atrrts JGJV,
Fèrrara R, Torri V, Hèjl*h TA, Tak8da K, Naqash AR, Gar8ssino M, P8tars S, W8kalaè H, Nass8r AH,
Ricciuti 8. J Immunother Cancer. 2025 Feb 4-,13121."e010674. doi". 10.1136fiitC-20244)10674. PMID".
39904562; PMCID.. PMC11795382.
Ng8n HYS, Seckl MJ, Berkowilz RS, Xiang Y, Goifier F, Sekharan PK, Braga A, Garrtrtt A.Int J Gynaeo)I
Obstat. 2025 Sèp,'171 Suppl 1 (Suppl 11.'7&86. th)i'. 10.1002tijgo.70275. Epub 2025 Jul 9. PMID." 40631439.
Rimini M. Fornaro L. Ikeda M. Abidoye O. Lucchetb J, Anionuzzo L. Kim JW. Nicheiti F. Saborowski A,
Pres5i8ni T, VIv81di C, Rapp05elli IG, Pe8t8rs F. Braconi C, Pin8to DJ, T8rnburini E, Pirch8r C, Tamberi S,
Castet F, Verrico M, Pansi A, Coutts N. Chon HJ, Martsrena A, Lamarca A, Landriscina M, Fimkeltneier F,
Oneda E, Avallone A. Dell'Aquila E, Perkhofer L. Kim IH. Pinto CMS, Garajova I, Kang B, Corallo S.
Fenocchio E. Farinea G. Pastorino A. Diana A. Changhcx)n Y. Schirripa M, Rodriquenz MG, Scartozzi M,
Zumstein L. Ghidini M. Prager GW. Aprile G. Spinelli GP. Yvn*Yeh S. Chan S. Waminglon E. Lan¢ianese
A. Bekaii-S3ab T. Lavawhi D. Kang M. Lonardi S. Vogel A. Prete AA. Bozzarelli S. Salani F. Persano M,
Ma51 G, Balsano R, Niger M, Camera S, Pa55eri L, FerTara M. Satake T, RiTnassa L, Ca5adei-Gardini A.
Liver Int. 2025 Dec-,45112).'e71H28. doi.. 10.1111fliv.70428. PMID". 41221651- PMCID.. PMC12606517.
ni
Cabibbo G, Celsa C, Battaglia S, Enea M. Di Maria G, Grova A, Ciccia R,
Manfredi GF, lavarone M, Vogel A, Singal AG, Reig M, Pinato DJ, Camma C.
Clin Cancer Res. 2025 Feb 3-31131."543-550. dTh= 10.11581107&0432.CCR-24-2582. PMID.. 39576248.

THE CANCER TREATMENT AND RESEARCH TRUST
TRUSTEES REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
Efficac
of atezolizumab Iu5 b8v8CIZUrn8b for unr8sectsbl8 HCC.. S tematic r8view and m8t&8nal
real-world evidence
Manlredi GF, Fulgenzi CAM, Celsa C, Stefanini B, D'AlessK¥A. Pinter M, Scheiner B, Awosika N, Brunetti L,
Lombardi P, Latchlord C, Lee PC. Huang YH. Lin CY. Dalbeni A, Vogel A. Galle PR. Kudo M. Rimassa L,
Chon HJ. Cabibbo G. Piscaglia F. Camma C. Pillai A. Pirisi M. Singal AG. Pinalo DJ. JHEP Rep. 2025
22..7181'.101431. doi.. 10.1016fi.jhepr.2025.101431. PMID- 40677696.. PMCID.. PMC12269603.
sis of
hi
Cabibbo G. Celsa C. 8hoori S. Reiberger T. Pinato OJ. Camma C. J Hepatol. 2025 Oec.'83161-.144&1451.
oi.. 10.101611 jhep.2025.07.020. Epub 2025 Aug 5. PMID.. 40759204.
EAD
rrn
EDF
Garbe C. Amaral T, Peris K. Hauschild A. Arenberger P. Basset-seguin N. Basthott L. Bataille V, Brochez L.
Del Marrnol V. Oréno B. Eggermont AMM. Fargnoli MC. Forsea AM. Holler C. Kaufm8nn R. Kelleners-
Smeets N, L8llas A, Lebbè C, Leiier U, Lon90 C, Malvehy J, MorenTrRamirez O, Nathan P, Pe118cani G,
S8189 P, Stockflelh E, Str81igos AJ, Van Akkooi ACJ, Vièira R. Zalaudek l. Lorigan P, M8ndala M,. Eur J
Cancèr. 202S Jan 17,'215.
Sacco JJ, Kirk P, Leach E, Shoushtari AN, Carvajal RD, Britton-Rivet C, Khakw S, Collins L, de 18 Cruz-
Mèrino L. Eroglu 2. Ikèguchi AP. Nathan P, Hamid O. Butlèr MO. Stanhopè S. R8nadè K, Sato Rèp Mèd.
2025 Apr 15'.6141.
Norton B, Sennf811 S, Nortley R, Hill P. Nathan P. lodice V, Zarattr-Lopez N, Carr A. Cureus 2025 Sttp 22.,17
191.. 892896. doi.. 10.77591eurèus.92896. ècollèction 2025 Sèp. PMID.. 41141128.
Chee D. Ya Ong CE, Tan DJH. Schal¢enberg JM. loannou GN. Huang DQ.. HCC
Policy Study Group. Clin Gaslroenterol Hepatol. 2025 May 12.. S1542-3565125KJ0364-7. doi.. 10.10161
j.cgh.2025.04.014. Epub ahead of prinl. PMID.. 40368132.
tsde-
tora
oni
soci
Celsa C. Pennisi G. Tulone A. Ciancimino G. Vaccaro M. Infantino G. Di Maria G, Pina¢o DJ. Cabibbo G,
Enea M. Mantovani A. Tilg H. Targher G. Camma C. Pell
S. Gut. 2025 Apr 7.,74151'.81M24. doi.. 10.11361gutinl-2024-334591. PMID.. 40015951.
He
alO￿llular carcinoma in
wtth HIV
Fulgenzi CAM, Dalla Pria A. Leone AG. Celsa C, Cabibts) G, Scheiner B, Pinter M, D'Alessio A, Zhao Y,
Brau N. Bower M. Pinalo DJ. J Hepalol. 2025 Oct'83{41.'971-981. doi.. 10.10161j.jhep.2025.04.028. Epub
2025 Apr 30. PMID.. 40316049.
Host-related Deterrninants of Res
nse to Im￿Un0thera
in Non-
osilion Metabolism Sex and Immune Re
ulalion
Santo V. Brunetti L. Pecci F. Peroni M. Bamini G. Paoloni F. Buti S. Tiseo M. Riccjuti B. Pinato DJ. Cortellini
A. Curr Oncol Rep. 2025 D￿..271121.'1427-1447. doi. 0.10071s11912-025-01718-7. Epub 2025 Dec 23.
PMID.. 41432903,. PMCID.- PMC12743683.
Cancer.. Th Inter
tsf

THE CANCER TREATMENT AND RESEARCH TRUST
TRUSTEES REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
Immune Check
Olnt Inhibitor5 for Patients With Preexistrn
Autotmrnune Neurol
Fletcher K. Machaalani M. El Hajj Chehade R. Nassaf AH. Nawfal R, Manos M.
Menzies AM. Aboubakar-Nana F, Hassel JC. Pinato DJ. Johnson A, Olsson-8rown AC, Carfino MS, Malgeri
A. Cortellini A, Singh A, Parikh K. Kim SY. Naqash AR. Long
GV. Challa P. Choueiri TK. Sharon E. Shah S. Johnson DB. JAMA Netw Open. 2025 Jun 2..8161'.e2513727.
doi.. 10.10011j8manetworkopen.2025.13727. PMID.. 40465294,. PMCID.. PMC12138719.Imrnuno
h8no
rwi
ic Disorder5
Barrichello APC. Elkrief A. Ricciutr B. Ganla T. Marron TU. Wang X. Lotter W. Lindsay J. Santo V, Cortellini
A. Sharma B. Felt K. Pf8ff K. L8mberti G. Pecry F. Federico AD. Makarem M. Gandhi MM. Nguyen T.
Haradon D, Vaz VR, John50n BE, D8bnath N, Wan9 Y. Kuang AG, Saeed A, R8dford M, Lovly CM, N8bh8n
CA, Pinatts DJ, Rodig SJ, Schoenleld AJ, Awad MM, I￿e$s1 JV, Naqash AR. Tumor Clin Lung Cancer. 2025
Jun',26141'.288-298.88. doi.. 10.1016fi.cllc.2025.01.014. Epub 2025 Feb 4. PMID.. 40021433.
Imm
Fulg8nzi CAM, D'Alèssio A, Pinato DJ. JAMA On¢ol. 2025 Fob 1.,11121.'188-189. doi.. 10.10011
jamaoncol.2024.S819. PMID". 39724320.
De Martin E. Fulgenzi CAM. Celsa C. Laurent-Bellue A. Torkpour A. Lombardi P. D'Alessio A. Pinato DJ.
Gul. 2025 Jun 6.,74171'.1165-1177. doi.. 10.11361guunl-2024-332125. PMID.. 39658265.
Pinalo OJ. J Hepatol. 2025 Nov:83151".1232-1233. 10.1016fJ.jhep.2025.07.018. Epub 2025 Sep 5.
PMID.. 40914644.
Salo T, Butler MO. PipemtrNeumann S. Hassel JC. Nathan P. Shoushtari AN, Rutkowski P, Carvalal RD,
Baurain JF, Schlaak M, Piulats JM. Sullivan RJ. Ochsenreither S. Dummer R, Kirkwood JM. Ikeguchi A,
Joshua AM. Middlelon MR, Edukulla R. Pfeiffer C. Sacco JJ Clin Can￿r Res. 2025 Sep 12. doi..
10.115811078-0432.CCR-25-1513. Online ahead ol print. PMID.. 40938927.
Nassar AH, Kim C. Adeyelu T, Bou Farhat E, Abushukair H. Rakaee M. Matteson
K, Lau SF, Takabe Y, Ocejo A. Ardeshir-Larijani F. Leal T. Ramalingam S. Alam S,
Gray JE. Hicks J. Kaldas D. Baena J. Ber)aga MZ. Nana FA. Grohe C. Leuders H.
Citarella F. Cortellini A. Mingo EC. Pancirer D. Das M. Elli5-Caleo TJ. Cheung
JM, Lin JJ, Watson AS, Carnidge DR, SridharA, Parikh K. CrovAey F, Marron TU,
Aggarwal V, Ahmed M, Sankar K, Kawtharany H, Zhang J, Owen DH, Li M. Nagasaka M, Pinato DJ,
Awosika N, Alhamad K. Puri S. Zaman U. Gupla DM. Lau C. Khan H, LiaLM J. Velazquez Al, Brown T,
Moliner L, Mosteiro M. R(￿ha P. Evans M. Vanderwalde A. Elliott A. Nieva J, Lopes G, Ma PC. Borghaei H,
Lee M. Young L. Aljumaily R. Mirza H. Kwialkowski DJ. Herbst RS. Flavell RA. Naqash AR. Chiang AC. Nat
Commun. 2025 Aug 19,.16111.'7717. doi.. 10.10381s41467-025-63091-O. PMID.. 40830141,. PMCID..
MC12365225.
ration of translational research in
hase I
Is=As
stematic review of breast cancer studies in
Giannone G, Lombardi P, Filelli M. Paparo J. Rognone C, Stefanizzi S. Valsecchi AA, Zumstein L, McNeish
IA, Pinato DJ, Gennari A, Daniele G. Di Maio M. Breast. 2025 JLJn,' 81..104431. doi.. 10.10161
j.brea5t.2025.104431. Epub 2025 Mar 6. PMID." 40132394", PMCID." PMC11984566.
of
rkm
Celsa C, Di Maria G, Lornbardi P, DAessio A. Fulgenzi CAM. Brunetti L, Manfredi GF. Stef8nini B,
Spaiacino A, Rigamonb" C, Pirisl M, Lalchford C, Vaccaro M, Enea M, Carntna C, Cabibbo G, Pinato DJ.
JAMA Oncol. 2025 Oct 1".11l101".116￿ll68. (kni.- 10.1001fjamaoncol.2025.2470. PMID." 40810932-, PMCID."
PMC12355390.

THE CANCER TREATMENT AND RESEARCH TRUST
TRUSTEES REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
Intem8tional CCA Consensus Consortium. Cholan
unmet needs and
riorities
Banales JM, Rodrigues PM, Affa S, AJ)dersen JB, Aspichuela P, Boulter L, Bridgewater J, Calvisi DF,
Cardenas A, Cardinale V, Carpino G. Coulouam C. Dopazo C. Edeline J, Fabris L. Folseraas T, Forner A,
Goeppert B. Heikenwalder M. Kendall TJ. Khan SA. Klampen HJ. Koerkamp BG, Lamarca A. Lindsey S.
Lleo A. Luedde T. Macias RIR. Moremenl H. Nault JC. Olaizda P. Perugorria MJ. Raggi C. Rimassa L.
Saborowski A, Valle JW, Vithayathil M, Vogel A, Braconi C,. N8t R8v Gastroenterol H8patol. 2026 J8n,'23
111'.65-96. doi.. 10.10381s4157M25-0115&w. Epub 2025 Dec 10. PMID.. 41372578.
iOGqrianoma 2026.. ststus
uo
Galle PR. Reck M. Pinato DJ. Garcia-campelo R. Finn RS. Cousin S. Zanghi J. Bemaards CA. Swanson
SJ, Morris S, Song Y, Peters S. Cancer Treal Rev. 2025 Nov.. 140..103016. doi.. 10.10161j.ctrv.2025.103016.
Epub 2025 Au9 25. PMID.. 40886486.
Lombardi P. Kim JS. Manfredi GF. Celsa C, Fulgenzi CAM. O'Alessio A. Stef8nini B. Doshi NC. Warmiroton
E, M8rron TU, Pinter M, Scheiner B, Kang B, Lim HY, Hsu WF, Wietham B, Silletta M, Parisi A, Lin CY.
Dalb8ni A, Masi G, Schanl8in M, von Felden J, Pisca91ia F, Galle PR, Kudo M. Pressi8ni T, Rimassa L,
Pirisi M, Cabibbo G, Chon HJ. Pinato DJ. JHEP Rep. 2025 Sèp 23",71121.'101S95. doi.. 10.10161
j.jh6pr.2025.101595. PMIO." 41321927.. PMCID.. PMC12657762.
Cortellini A, Garbo E, La Cav8 G, Ciiar8lla F, Santo V, Brun8tti L, Pinalo DJ, Nèidoo J, Loza M, Gonova C,
Getlinger S. Kim SY. Jayakrishnan R. Zarif TE. Russano M. Peca F. Di Fed&rico A. Montrone M, Owen DH.
Signorelli D. Li M, Camerini A. Halmos B, Vincenzi B, Metro G. Yendamuri S, Grossi F. Josephides E,
Tomasik B. Giusti R, Bria E. Sebastian M. Rost M. Acker F, Landi L. Mazzoni F. Morabito A, Leonetti A.
Cantini L, Mountzios G, Kalvapudi S. O'Reilly D. Karapanagiolou E. Monnel I, 88en8 J. Macerelli M. Majern
M, Piedra A, Cortinovis DL, Tonini G, Minuti G, Mezquiia L, Go)rria T. Beninato T, Lo Russo G, Prel8J A, De
Giglits A, Bièllo F, Nana FA, Dingamans AC, Aèrts JG, Fèrnara R, Abu Hejlèh T, T8kad8 K, Naq8sh AR.
Garassino MC, Wakèlè& HA. Nassar A. Ricciuti B, Soda P. Canjso CM, Guarrasi V. Lung Cancer. 2025
Nov., 209-.108799. doi.. 0.1016fi.lungcan.2025.108799. Epub 2025 Oct 16. PMID.. 41108882.
Swift BE, Cooprnans L, Singh K, Coyl• C. Wilkès EH, Jabbar l. Mahèr G, Aguiar X, Salman L, Palmèr JE,
Sarwar N, Caldwell R, Ghorani E, Kaur B, van Trommel NE. Lok CAR. Winter M, Seckl MJ.BMJ Med. 2025
Apr 23..4111'. e001017. doi.. 10.11361bmjmed-2024-001017. ecollection 2025 Jan.PMID'. 40309224.
Joyce CM, Maher GJ, Dineen S, Suraweera N, Mccarthy TV, Coulter J, O'Donoghue K, Seckl MJ,
Fitzgerald 8.J Clin Pathol. 2025 Apr 17,'78151'.327-334. doi.. 10.1136ficp-202&209269.PMID". 38555105.
Ascierto PA, Del Vecchio M. Merelli B. Gogas H, Arance AM. Dalle S. Cowey CL. Schenker M, Gaudy-
Marqueste C, Pigozzo J. Marquez-Rtxlas l. BuU8r MO, Di Giacomo AM, Gligich O, De La Cruz-merino L,
Arenberger P, Atkinson V, Nathan P, Hill A, Millwai¢J M, Fecher LA, Khushalani Nl, Queirolo P, Soomro R,
Rathod D. Askelson M, Pe Benilo M. Joseph D. Larkin J. N Engl J Med. 2025 Oct 18. doi.. 10.10561
NEJMoa2504966. Online ahead of prinl. PMID.. 41124198.
r liv
Pinato DJ. J Hepatol. 2025 Jul",8311}."27&274. d￿". 10.1016tI.jh8p.2025.03.025. Epub 2025 Apr 25. PMID..
40287289.
Pin8lo DJ. J Hepatol. 2026 J8n;84{11'.233-234. doi.. 10.1016fi.jhep.2025.11.001. Epub 2025 Nov 20. PMID..
41271523.

THE CANCER TREATMENT AND RESEARCH TRUST
TRUSTEES REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
Phase I dos8-escAlation and harm8CA)d
advanced so11d tumors
Luke JJ, Pinato DJ, Juric D, LoRusso P, Hosein PJ. Desai AM, Haddad R, de Miguel M, Cervantes A, lfjm
WS, Marabelle A, Zhang Y, Rong Y. Yuan X. Champiat S.
J Immunother can￿r. 2025 Feb 20.'13121'.e010511. doi.. 10.1136fiitc-2024-010511. PMID.. 39979069..
PMCID.. PMC11842995.
amic stud of STING
onist E7766 in
TD
Lok C. van Trommel N. Br8icu El, Planchamp F, Berkovmtz R. Seckl M.. EOTTD-ESGO-GCIG-ISSTD
Guid81ine Committe8.J Clin OrKol. 2025 Jun 20..431181'.2119-2128. doi.. 10.121JOIJCO-24-02326. Epub 2025
May 13. PMID." 40359461.
Scheiner B, Lornbardi P, D'Alessio A, Kirn G, Talawoghi M, Petrenko O, Goldin RD, Fulgenzi CAM.
TorkpourA, Balcar L, Maun FA, Pornej K, Hirnmelsbach V, Barsch
M. Celsa C. Cabibbo G, Cheon J. Krall A. Huckè F. Di Tommaso L. Bemasconi M,
Rimassa L, Samson A, Stelanini B. Mozayani B. Trauner M, Lackner C. Stauber R.
Vasuri F. Piscaglia F. Bengsch B. Finkelmeier F. Peck.Radosavljevic M. Rasmussen
Busund LT. Marafioti T. R8hbari M. Heikenwalder M. Pinter M. Chon HJ. Rakaee M.
Pinalo DJ J Immunolher C8n¢•r. 2025 Od 5..131101.'eO10975. doi- 10.1136fiil¢-2024-010975. PMID..
41052888; PMCID.. PMC12506175.
Takada K, Shimokawa M, Cortellini A. Pinato DJ. Mizuki F. Tak8mori S. Lung Cancer. 2025 Nov,.
209..108787. doi.. 10.10161j.lungcan.2025.108787. Epub 2025 O¢t 10. PMID.. 41105995.
Amarnath Challapalli. Pranlik Das. Anand Shamia. Rajanee Bhana. Alison Jane Birtle. Dakshinrnoorthy
Muthukumar. Manreel Randhawa. Sanlhanam Sund8r. Mark Prentice. Diletts Bianchini, Emily Renninson.
Mi9uel Capomir, 1s8bel Syndikus. K8malr8m Thippu Jayapiakash, Thiraviyam Elumalai, Sarah G¢)o(Jwin,
Omi Parikh, Paul While, Emily Foulston•. Joumal of Clinical Oncol(MJy 2025 43..5 suppl, 89-89.
Shah H. Phillips J, Dhanjal MK. Dassan P, Seckl M. Frise C.Ob5tet Med. 2025 Jul 4..1753495X251354997.
doi.. 10.117711753495x251354997. Online ah88d of prinl. PMID.. 4062106.
Re
roducible safe
and effica
of durvalumab
without tremelimumab for he
atocellular carcinoma
Celsa C. Pressiani T. Nishida N. Chamseddine SM. knind A. Li M. Fortuny M. Khaled NB, lavarone M.
Toy¢)da H. Rapposelli IG. Casadei-Gardirbi A. Wivaldi C. Ulahannan S. Andanamala H. Scheiner B. Pinter M.
Orfandi E, Fulgenzi CAM, Manfredi GF, Li)mbardi P, D'AleS5￿ A, Stefanini B, Villani R, Ponzi8ni FR, Stella
L, Caminats O, Rica AD, Gonzalez M, S￿raCin0 A, Di Maria G, Vaccaro M, Cabibbo G, Carnma C, Reig
M. Kelley RK, Singal AG, Kaseb AO. Kudo M. Rimassa L. Pinato DJ. JHEP Rep. 2025 Nov 0'.8131.'101685.
doi.. 10.10161j.jhepr.2025.101685. PMID.. 41675370.. PMCID.. MC12886069.
rwv
I With Imm
and Histol
Sub
es
Clin Genitourin Cancer. Bakaloudi DR, Talukder R, Enrighl T, Leary JB, Makrakis D, Diamantopoulos LN,
Hobeika C, Thomas VM, Swami U. Zakopoulou R. Bamias A. Brown JR. Pinato DJ, Latchford C, Jindal T,
Koshkin VS. MurgiAt J. mile11￿ M. Frobe A. Johnson J. Zakharia Y. Mva A. Nguyen CB, Hui G. Drakaki A.
RodrigLJez-Vida A. Rey-cardenas M, Castellano D. Buznego LA, Duran l. Barrera RM. M8rmolejo D,
McKay RR, Stewart TF, Barata P, Epstein IB, Bellmunt J, Yu EY, Raychaudhuri R, Nadal R, Vakar-Lopez F,
Gupta S, Wright JL, Khaki AR, Grivas P.
2025 Aug',23141.'102356. doi.. 10.101WI.dgc.2025.102356. Epub 2025 Apr 14. PMID.. 40378559.
With

THE CANCER TREATMENT AND RESEARCH TRUST
TRUSTEES REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
Retros
ectiv8 multic&nter 8n81
rnetastatic uveal melanoma
Ciemik A, Ciernik L, Bonczkowtz P, Morak M, Heinzeding L, Bennaceur Y, Lavless A, Sullivan R, Kott J,
Gebhardt C, Carter TJ, Nathan P. Tschopp S. Dummer R, Ramelyte E. Oncologist. 2025 Jul 4., 30
171'.oya1173. doi.. 10.10931oncololoyaf173.
is of rea￿lIfe toxi
and outcome of i
ilimum8b 8nd nivolumab in
Safet
and 8fficac
of irnrnun8 check
int thera
for th8 tr88tm8nt of ati8nts with Gqrdiac m8t85t8SiS'.
Nassar AH. Abou Maiwi S, El Zarif T. Denu R. Macaron W. Abdekwahab N, Freeman D. Vasbinder A,
Hayeck S. Anderson E, Goodman RS. Johnson DB. Grynberg S. Shapira R. Kwan JM. Woodlord R. Long
GV. Haykal T. Dent S. Kojima Y. Yonemor K. Tandon A. T￿VIn0 A. Akhter N. Yang EH. Hui G. Drakaki A. El-
Am E, Kozaily E. Al-Hader A Bou Farhat E. Babu P. Mittra A. Li M. Jones N. Baena J. Juarez Herrer8 M.
Foder8ro S, Nana FA, Kim C, Sackstein P, Pankh K. Desai AP, Smith C, Cort8llini A, Pinato OJ, Korobwicz
J, Lopetegui-Lia N, Funchain P, Chtsudhary A. Asnani A, Navani V, Meyers D, Stukalin I, Oceio Gallegos
JA, Trent J, Nusral S, Malvar C, McKay RR, Neilan TG, Chou8iri TK, Naqash AR. J Immunoth&r Cancer.
2025 Mar
3..13131'.e009364. doi. 10 11361jitc-2024-009364. PMID.. 40032601.. PMCID.
PMC11877189
ni
Qas P, Sharma A.th1Oba￿ R.A.A,Jknlo J. YthumL3￿￿Sl320 September 2025.
in h
Salia H, Wi5cher L. D'Ales5io A, Godbole I, Suo Y. OttTrMora P. Beck J,
Neum8nn O. StÈnzing*rA, Schirmachbr P, Fulgènzi CAM, 81aum6is8rA. 808rriès M,
Roehlen N, SchulthèiAY M, Hofmann M. Thimmè R. Pinalo DJ, Longerich T. Bèngsch B. Gut. 2025 Fab
6,"74131'.451-466. doi." 10.11361gutjnl-2024-332837. PMID.. 39349005,. PMCID.. PMC11874287.
Sehreèdar B, Pr8sad P, Gb8d6gèsin O, Gupla S. Ffazèr R, Hèanèy S, Franks H. Blair C, Stutt8rd M,
Badow C, Cook H, Winter H. d'Anenzo P. Symington J, Radrf Y. Rampes S, Nathan P. Young K, Shaw H,
Carr A. Willis M.
Cancers (Basell. 2025 Dec 9:171241'.3935. doi.. 10.33901cancers17243935.
HIV
Fulgenzi CAM, Dalla Pria A, Leon&AG, Martinez M, Del Peral EFM. Fk)res ME.
Bower M. Pinato DJ. BMC Cancer. 2025 Jul 1'.25111'.1104. doi." 10.11861s12885-025-14326-2. PMID..
405969)9; PMCID.. PMC1221W1.
Comanici M, Robertus JL, Rice A, Nathan P, Anikin V Melanoma Res. 2026 Feb 1,36111..70-74. doi..
10.10971CMR.00(x)O￿0[￿jOolo66. Ewb 2025 Oct 17. PMID: 41097815.
Martirena A, Lombardi P. Pinato DJ, Rimaw L. Larnarca A. ESMO Gastrointest Onool. 2025 Fgb
17.,7..100139. doi." 10.1016fJ.8smogo.2025.100139. PMID". 41646488," PMCID.. PMC12836512.
S stemic treatment in
atients with he
tocellular carcinoma and advanced liver d function
Pinter M. Fulgenzi CAM. Pinato DJ. Scheiner B. Gul. 2025 Jun 6.'74171=1178-1188. d￿.. 10.11361
gutjnl-2025-334928. PMID.. 40301119.
Tertia I m
hold structurè d
ami(s at Ihè centre of immunother
nse in he atocellular carcinoma
Pinalo DJ. J Hepatol. 2025 Apr.,82141..76￿77O. doi." 10.1016fJ.Ihep.2024.12.040. Epub 2025 Jan 21. PMID..
39843298.

THE CANCER TREATMENT AND RESEARCH TRUST
TRUSTEES REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
Th8 2024 ILTS-ILCA cons8nsu5 reC￿MMendatiOnS for liver trans
cholan
iocarcinoma
Kodali S, Kulik L, D'AJlessio A, De Martin E, Hakeem AR. Lewnska M, Lindsey S, Liu K, Maravic Z, Patel
MS, Pinalo D, Rammohan A, Rich N, SandLttZi ZaMpa￿lI1 M, Victor DW 3rd, Vinaxia C, Brombosz EW,
Villanueva A. Meyer T. Selzner N.
Ghobrial RM, Rela M. SapiscKhin G.. and the ILTS ILCA Consensus 2024 Group
Liv8r Transpl. 2025 Jun 1..31161'.81&831. doi.. 10.10971LVT.IM)00000000000589. Epub 2025 F8b 28. PMID..
40014003.
ant8tion for HCC and intrahe
8tic
Cabibbo G. Fkn'massa L. Lamar¢a A. hAasi G. Daniele B. Pinato DJ. Casadei-Gardini A. Cancer Treat Rev.
2025 Jun',137..102955 doi.. 10.1016fi.ctrv.2025.102955. Epub 2025 May 9 PMID.. 40373702.
Ng K. Ganguli S. Rajan P. Sharma A. Shamash J. Joumal ol Clinical Oncology 2025 43'.5_suppl. 644.644.
TIM
INT
inin
PAwith
IMT
EBPA i
Plummèr R. Sodergren MH, Hodgson R. Ryan BM. Rèull N. Nicholls JP, Reebye V.
Voutila J. SinKJaglia L. Meyer T. Pinato DJ. Sarker D. Basu B. Blagden S. Cook
N. Jeffrey Evans TR, Yachnin J. Chee CE. Li D. El-Khoueiry A. Diab M. Huang KW.
Pai M. Spalding D, T81bol T. Noel MS, Keenan B. Mahalingam D, Song MS. Gros50 M, Amaud D. Augusle
A, Zacharoulis D. Storkholm J, M¢Neish l. Habib R, R05si JJ.
H8bib NA. Cèll R8p Mad. 2025 Apr 15.,6141.'102041. dtsi.. 0.1016fi.xem1.2025.102041. Epub 2025 Mar 31.
PMID.. 40168999,. PMCID.. PMC12047497.
Cortellini A, S8nlo V, Brunetti L, Garbo E, Pinalo DJ, L4 Cava G, Naidoo J, Katz A. Loza M. Ng81 JW.
GÈnov8 C. Gèth'ngèr S, Kim SY, Jay8krishn8n R. El Zaril T, Russano M, Pacci F, Di F8d6ricts A, Alèssi JV.
Montrone M, Owen DH, Ramella S, Signor&lli D. Fidltsr MJ. Li M. Camerini A, Halmos B, Vincenzi B, Metro
G, Passiglia F, Yendamuri S. Guida A, Ghidini M. D'Alessio A. Banna GL. Fulgenzi CAM, Grisanti S. Grossi
F. O'lncecco A. Josephides E. Van Hemelrijck M. Russo A. Gelibter A, Spinelli G, Verrico M. Tomasik B.
Giusli R. 8alachandr8n K. Bria E. Sebastian M. Rosl M. Forster M. Mukheriee U. Landi L. Mazzoni F,
Avjayeb A, Dupont M, Curi<)ni- onlewlrg A, Chiari R. Sforza v, fiseo M, Friedlaender A, Addeo A, Zor8tt9
F, De Tursi M, Cantini L, Roca E, Mountzios G, Rocco D. Dèlla Gravara L. Kalvapudi S, Innts A, Bironzo P,
Di Marco Barros R, O'Reilly D. Fitzpalrick O. Karapanagiotou E. Monnet I, Baena J, Macerelli M, Piedra A,
Agustoni F, Cortinovis OL, Tonini G. Minuti G. Bennati C. Mezquita L, GorrAa T. Servetto A, Beninato T, Lo
Russo G. Prelaj A. De Giglio A. Rogado J. Moliner L. Nadal E. Biello F. Nana FA. Dingernans AM. Aerts
JGJV. Ferrara R. Abu Hejleh T. T8kada K. Naqash AR. G8ra5sino MC. Pe¢ers S. Wakelee HA. Nas5ar AH.
RicciLJti B, Sod8 P, Caruso CM, Guarrasi V. J Iwnmunoth8r
Caneer. 2025 Sep 29",13191'.e012423. doi". 10.1136tjitc-2o2￿l2423. PMID..
41022528; PMCID.. PMC12481261.
rn
Abdul Aziz N, Masangwi DD, GarvJuli S, Sh8wTha A. Ng K, Rajan P. Sham8sh J. Th8rAdv M8d Oncol. 2025
Aug 30.
Craddock C. Earwaker P. Fittall M. Fontana E. Ganesh D. Gerlinger M. GhafiK)r
Q, Jones RP, Kunene V, Lee L, Lee R, Lee SM, Linch M, Little M, Liu J, mcKen￿e
H, Petty R, Pinato DJ, P0￿e5 T, Protheroe A, Robin50n T, Ross PJ, Shiu KK, Spicer J, Symeonid6s S,
rilby M, Vimalachandran D, Wang JY. Wardley A. Winter H. Camb Prism p￿c1S Med. 2025 Jan 20',3.'e1.
doi.. 10.10171pcm.2024.5. PMID= 39944656". PMCID.. PMC11811843.
10-

THE CANCER TREATMENT AND RESEARCH TRUST
TRUSTEES REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
UK wei
ht and w811n8ss r85earch consorburn. Im
cl of GLP-1 rec8
tora
onist-induced wei
hl loss on 22
cancers In the nexi ten
ears usin
Markov state-transition model - A UK wei
ht and wellness cancer
landsca
e anal sis
Dong J, Starkey T, Cheng VWT. Clark J, Pinato DJ, Robinson T, filby M. Tumbull CD. Yw Lee L.. Cancer
Epidemiol. 2025 Aug.. 97.'102837. doi..
lo.101￿l.C8nep.2025.lO2837_ Epub 2025 May 24_ PMID.. 40413897_
Carter TJ. Broadloot J, Coupland SE, Damalo 8. Evans H. Fenwck S, Khoia L, Krausa T, Lewis R, Nathan
P. Modi S. Negretti G. Rashid S. Sacco JJ. Shaw H. Sisley K. Sowton R, Turajlic S. Turnbull N. Woraker A.
Wheater M. Eur J Cancer. 2025 Oct 1.. 228..115687. doi.. 10.1016fi.eJca.2025.115687. Epub 2025 Aug S.
PMID.. 40885127.
Flnanclal r•vl•w
The finan￿81 result5 for the year are as shown in th8 financial Section of his report and ¢over acwunting period of
12 months frorn 01 January 2025 10 31st December 2025. The carry fO￿ard funds as at 31st December 2025
amount8d to £1,639,194, of which £1,28S,843 was unrestricted and £353,551 was restrfcted.
Total income lor the year was £325.771 12024.. £502.1511. derived primarily from donations and investment income.
Total expenditure was £283,83112024 £142,202), rnainly relabng ¢0 ￿SearCh granls and sUPPOrt costs.
Th$ tru$lsg$ consid&r th& ¢harily to be a going COn￿M. with $uffio$nt to m$*t obligations lor at1g8$1 the
n8xl 12 months.
Plans for future p•rlods
Inv•8tlng In fundral8lng
Following her temporary appointment in 2025. Mrs Frankie Britten has been offered a pemanent position as
Fundraising Manager, commencing in 2026. This will allow the charity to place greater focus on fundraising and
income generation, while enabling Mrs Laura Brown lo concentrate on stralegic and operatsonal matters.
Plan$ for r•$oareh
CTRT will continu6 lo support a divarsè variaty of f8s&arch into many cancars including $8vèral diffarant typas of
less common cancers such as ovarian. ulenne. melanoma and also very rare cancers such as gestationa
trophoblastic disease IGTOI. germ cell lumours and rare gynaecological cancers. Our research supports clinical
studie5 as well as laboratory locused work such as developing novel biomarkers. lrnmunotherapy continues to be a
major area of interest in ¢he cancer worfd and CTRT SUPkX)rts research studying the effects of immun(therapy in
trophoblastie, lung and wnal eancèrs.
CTRT are currently trying to deveh)p ways to avoid the use of toxic multi4rug chemotherapy to treat GTD by
running a trial of imrnunotherapy treatmenl. This lrial is a major fundraising focus for CTRT in 2026.
11

THE CANCER TREATMENT AND RESEARCH TRUST
TRUSTEES REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
RISK MANAGEMENT
The Trustees are aware of the risk5 affecting the Twst and its work and have ensured that polici￿ are in p18ce to
mitigate the effect ol these risks.
Flnanclal rl$ks and Inveglment
A key aim of the Board is to ensure CTRT holds adequate reserv85 for working caprtal purposes and has sufficient
fLJnds to rneet contractual li8biliti85 and wnding dovm costs, if the organisats'on were to cJos8. Thi5 includes
redundancy pay, amounts due to creditors and commitments under contracts. CTRT'S level of reserves also helps
the organisation lo plan expenditure against variations in the way funding is received. To balance tt)e uncertainly of
funding, our policy is to maintain financial ￿ServeS to cover these costs and allow lor an orderly wind down. The
current estimate of these costs is c £65.000. Without cu￿ent level of support from our individual donors and based
on current expenditure levels. CTRT is estimated to still remain in a position to cover these c05t5 for the corning 12
months As our unr8strict8d rèservès st8nd at abotjt £1.2m.
Govèrnanco strudu
The review of governance structure. pdicies and procedures was commen&ed and following that review. any
recommendations rnade and agreed upon by Ihe Iwstees will b8 implemenieLI in Ihe authorised order.
StTu¢tur•* gov¥rn•n¢g ond rn•n•9em¥nt
The trustees who served during the year and up to th8 date of S￿natUre ofthe financAal ststements were..
Mr Russell Hallam
Dr Paul Nathan
Dr A Sharma
Dr David Pin810
Prol. Michael Seckl
Prol. Gordon Rustin
Ms Kirandèèp Grèwal
Dr Ehsan Ghorani
Mr Glèn Williams
Professor Marcia Hall
(Appointed 17 May 20261
(Retiremenl 31 July 20251
RESERVES POLICY
The Iruslees. policy is ¢0 maintain Suff￿lent reserves io cover WJ years of the charity's operabng costs. together
wilh the funding required ¢0 meet exisling research cornrnilments. This is intended to provide financi81 stability in the
ewnt ol 8 r9duction in don8tion$ and $nsurs thal th$ ¢harity ¢an Continuo to m￿1 its oblKJatK)ns.
Annual operating costs are currently estimated at approximately E65,000, giwng a minimum operats'ng reserve
requirement of £130,000, in addition to amounts requi￿ lor committed ￿searCh projects.
At 31 December 2025, the charity held unre5tricled lund5 of £1,285,643, of which £1,221,038 repr8sent8d fre8
reserves. Thi5 cornpares with the tru5tees' minimum operating reserve requirement of £130,000, together with those
funds required to meet existsng resèarch commrtmènts.
The trustees consider the level of ￿serveS held to be appropriate. laking into acwunl the charivs funding
commitments. ¢he uncertainty of fuiure donation income and its plans to continue supporting research projects.
Due lo the tirning of fundraising income and expendrture on charitatAe activitie5, the charity can hold significant cash
balances ahead ol planned eXpendrtu￿. The trustees have therefo￿ placed a proportion of these funds into
interesl-bearing deposit accounts. induding ￿tice accounls. whilsl maintaining sufficienl accessible funds to meet
the charity's ongoing commitments.
12-

THE CANCER TREATMENT AND RESEARCH TRUST
TRUSTEES REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
CONCLUSION
Research. either totally or partly funded by CTRT leil to 73 publicab.ons in 2025.
The Trustees are confident that CTRT will o)ntinue lo fvnd work Ihat will lead to improvements in the detection,
monitoring and treatment of cancer and care for palients with cancer.
The trustees r
port Was approved by the Board olTruslees.
Prol. Michael Seckl
Truslg9¥
Dalè,.
28/10/2026
13-

THE CANCER TREATMENT AND RESEARCH TRUST
STATEMENT OF TRUSTEES RESPONSIBILITIES
FOR THE YEAR ENDED 31 DECEMBER 2025
The trust8es are r8Stx)nsibl8 for pr8paring the Trustees R8POrt and the finana81 stat8rn8nts in 8ccordanc8 With
applicable law and United K"bngdom Accounting Standards Iunited Kingdom Generally Accepted Accounlin9
Practice).
The law applicable to charities in England and Wales requires the Injstees to prepare financial slatements for each
fin8n¢ial year which give a tnje and fair view of the stale of affairs of Ihe charity and of the incoming resources and
application of resources of the charity for thal year.
In prepanng these financial ststements. the trustees are required to".
select suitable accounting poliaes and then apply them consistently.,
- observe the rnethods and principles in the Charities SORP..
make judgements and estimates that are reasonable and prudent-
state whether applicable awounting Standards have been followed, subject to any material departures disc105ed
8nd explained in the financial statem8nls", and
prepare the linanaal slalemenls on the going concem basis unless it is Inappropriatè lo presun* that the charlty
will continue in operats'on.
The trustees are responsible lor keeping sufficient accounbng records thal disdose r88sonable accuracy at any
lime the financial position of the charity and enable them lo ensure that Ihe financi81 statements cornply with the
Charities A¢t 2011. th$ Charily IAc¢ounts and Reports) Regulations 2008 and the provisi(>ns of th& irust deed. Thtry
arè also r*sponsibl6 lor safeguarding thè assets ol l+)è chanty aThJ hèncè lor takin9 rèasonablè stops lor thè
prevention and detection ol fraud and olh6r irregularities.
14-

THE CANCER TREATMENT AND RESEARCH TRUST
INDEPENDENT EXAMINER'S REPORT
TO THE TRUSTEES OF THE CANCER TREATMENT AND RESEARCH TRUST
I r8POrt to the trust8es on rny ex8mination of th8 finana81 statements of The Cancer Tr8atm8nt and Research Trust
Ithe charity) for the year ended 31 December 2025.
Responslbllltles and basls of report
As the charity'5 tru5t8es you are r8SW)n5ibl8 for thg preparation of the 8cwunts in a￿)rd￿n¢9 with the
requirements of the Charities Act 2011 1.the Act'i.
I report in respect of my examinats'on of the charily s accounts carried out under section 145 01 the Act and in
carrying out my examination I have followed all the applicable Directions given by the Charity Commission under
section 14515Xbl of the A¢t.
Ind•p•ndènt •xamlnèr's stat•m•nt
Since the charity's gross income exceeded £250.000 your examiner must be a member of a body listed in section
145 01 th8 Act. I confirm th8¢ l arn qualified ¢0 undertake the examina¢ion b￿u￿8 l am a rnember of ACCA, which 15
on& ol the listèd bodiès.
I have completed my examination. I confimi thal no matters have rThne to my attention In CL*nnection with the
examination giving me cause to believe that in any material resp8cl'.
accounting racords were not kèpt in respect ol the d)arity as requirad by s8Ction 130 of lh& Charltlas Act 2011.
the financial ststements do not accord with those records., or
the accounts do not comply with the applicabl8 requirements concerning the lorni and content of aco)unts set
out in the Charities (Accounts and Reporlsl Regulations 2008 other than any requirernenl that the accounts
give a 'true and fair view, which is not a matter considered as part of an independent ex8rnin8tion.
I have no wneèms and havè ¢om¢ across no oth*r matters in ￿nn￿¢t1¢)￿ wrth lh& examination to which 8tt8ntion
shotild be dr?wn In thls
ort in ordgr to ènabts a wopgr und8tstandin9 01 thé financlal statémènts to ba ra8ch¥d.
Adam Shelley FCCA
Sobell Rhodes LLP
The Kineti¢ C¥ntr*
Theobald Street
Elstrèa
B0￿hamwood
Hertfordshire
WD6 4PJ
United Kingdom
Dated..
29/10/2026
15-

THE CANCER TREATMENT AND RESEARCH TRUST
STATEMENT OF FINANCIAL ACTIVITIES
(INCLUDING INCOMEAND EXPENDITUREACCOUNT)
FOR THE YEAR ENDED 31 DECEMBER 2025
Unr•strl¢ted R•strl¢ted
funds
funds
2025
2025
Total Unrèstrlcted R•strlcted
funds
funds
2024
2024
Total
2025
2024
Notes
Income from:
Donation and legacies
Inv8Stmenl
289.876
24,880
11,015
300,891
24,860
384.379
17.590
100,182
484.561
17.590
Total Income
314,756
11,015
325,771
401.969
100.182
502.151
Expendltur• on..
Raising funds
Charitable activities
Othèr èxpenditure
7,643
4.960
63.708
7,643
212.480
63,708
5,108
4.835
51.323
5,108
85.771
51.323
207.520
80.936
Total •xp•ndllur•
76.311
207.520
283,831
61.266
80,936
142.202
Nel gain$ on
Investments
51.834
51,834
Nét Incom•l1•x￿nd1IUr•l
290,279
1196,$05)
93.774
340,703
19,246
359,949
Transfers behyeen
funds
1208,814)
208.814
136.4471
36.447
Met movem•nt In
fundi
81,465
12.309
93,774
304,256
5S.693
359,949
R•conclllatlon of funds:
Fund balances at 1 January
2025
1.204,178
341,242 1.545,420
899,922
285,549 1,185,471
Fund balanc•s at 31
December 2025
1,285.643
353.551 1.639.194
1.204.178
341.242 1,545.420
The statement of financial ac1M￿S indudes all gains and losses reo)gnised in the year. All income and expenditure
derive frorn conts'nuing activities.
16-

THE CANCER TREATMENT AND RESEARCH TRUST
BALANCE SHEET
AS AT 31 DECEMBER 2025
2025
2024
Notes
Fixed assets
Intangible assets
Tangible assets
Investments
11
12
13
5.289
1.013
58,303
1.505
1.494
6,469
64,605
9,468
Current assets
Debtors
Investments
Cash at bank and in hand
14
15
32.797
765,979
848.842
10,274
1.591.696
1.647.618
1.601,970
Cmdltors.. amounts lalllng du• ￿thIn
one year
16
173.0291
166,0181
Not curr•nt a8Bets
1.574.569
1.535,952
Total •s¥•ts l•s¥ ¢urr•nt Il•bllltl¥s
1.639,194
1.545,420
Tho fund¥ of th¥ chaTIty
Restricted income funds
Unrèstrictèd funds
17
353.551
1.285,643
341.242
1,204,178
1,639,194
1,54S,420
Thè Ilnanclal statements w8r8 approv8d by thè tru$tèg$ on. 28/10/2026
Prof. Michael Seckl
Trust••s
17-

THE CANCER TREATMENT AND RESEARCH TRUST
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
Accounting policies
Charfty Infomiatlon
The Cancer Treatment and Research Twst is a exists to support treatment and research into many forrn5 of
malignant dis8as8 and has b8en particularfy Involv8d in Unde￿tandIng how certain cancer5 d8velop, finding
better ways to monitor them and develtsping new anli-cancer agents. 11 remains committed to funding research
that is not adequately lun¢Jed eilher by the major cancer charits.es such as CRUK, the MRC of the
phamiaceutical industry.
1.1 Ac¢ountlng convontlon
The financial slalemenls have been prepa￿ in accordance wth the charivs goveming document, the
Charities Act 2011. FRS 102 Yhe Financial Reporting Standard appliCa￿e in the UK and Republic of
Ireland" I'FRS 102.1 and the Chanties SORP "Accounting and Reporting by Charities.. Slalernent ol
Rewmmen(Jed Practice 8pplicable to Charities preparing their accounts in accordanc8 With the Fin8nci81
Rèporting Standard applicablè in Ihè UK and Rèpublic ol Irèland IFRS 1021. (èffective 1 January 20191. Thè
charity is a Public Benefit Entity as dèfined by FRS 102.
The charity has taken advantage of the provisions in the SORP for charities not to prepare a Stat￿ent of
Cash Flows.
Thè finan¢ial ststem*nts havo d¢partod from Chaniie$ IA¢¢ounts and Rèports) Règulations 2008 tsnly to
th& èxtant r￿Uired to providè a true an¢J lair vièw. This dèparturè has involv•d following thè Statamènl of
Recommended Practice for chanties applying FRS 102 ralher Ihan the version ol the Statement of
Recommended Practice which is relerred to in the Regulations bul which has since been withdrawn.
The financial st8lemenls are prepared in slerfing, which 15 Ihe functitinal currency of tho charity. Monetary
amounts in these financial Ststgments ar¢ tg Ihg nearg$t £ 1.
The financial statements have be•n pr8par8d und8f tha historfcal cost convention. The princlpol occountlng
policies adopted are set out below.
1.2 Golng concern
At the time of approwng the finanaal ststements. th& Injslees have a reasonable expectation that the charity
has adequate resources lo continue in operational existence for the foreseeable lulure. Thus the trustees
continue lo adopt the going concern basis ol accounting in preparing Ihe financial slalernents,
1.3 InGom•
All Incorne 15 recognistsd in thè Statèmènt of Financial Acti￿ti￿5 onc• thè charity has 8ntitl6m•nt to thè funds.
it is probable that the income ￿11 be received and lh& amount can be measured reliably.
Donations and legac4es are prowded lo the Charity. in order thal the Chanty can fuffil its purpose.
L•gacles
Legacy income is recognised ¥then receipt is probable. Ihe amount can be measured reliably. and notification
has been ￿ceiVed from the personal representatives thal Ihe estste acixjunts have been finalised or that
distributions can be reli8bly measureil.
Grant income
Grant income that is subject to perform8nc8 (xjndthons is retXYJniS8d when the charity has 8ntiUem8nt to th8
funds, it is probable that Income will be received and any performance condition5 have been rnet. Grants
thout performance conditions are recognised when the charity becomes unconditionally entitled to the
income.
18-

THE CANCER TREATMENT AND RESEARCH TRUST
NOTES TO THE FINANCIAL STATEMENTS {CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
Aeeounting pollelès
IContlnu•d)
Donated goods, Services and facilities
Where donated g(x)ds or Services meet the recognition criteria of the SORP, the income 15 recognised at the
lair value of the gotKls or s8Nic8s receiv8d. Where it is not practicable to reliably m8asur8 the vJue, th
income is nol recognised, but Ihe nature ol the donation is disdose(l in the trustees, report.
1.4 Expenditure
Liabilities are recognised as expenditure as swn as there is a legal or constructive obligation committing the
charity to that expenditure, it is probabl8 thal a Iransfer of economic beneffts will be required in settlement and
the amount ol the obligation carb ￿ rneasureil reliably.
Expenditure is accounted for on an accruals basis and has been dassified under headings that aggregate all
cost related to the category. whe￿ costs cannol be direcuy attributed lo partiwlar headings they have been
allocated to activ￿.e5 on a basis consistenl with the use of resources.
Governance and support costs
Support costs are those functions thal assist the work of the charity but do not direcfjy undertake charitable
activities. These include administrative and financi81 man8gernenl cosis. Where 5UPPOrt costs cannot be
directly attributed, they are apportioned to 8divilies based on an estimate of stalf time or another suitable
basls.
Govemance costs are the costs associated with statutory compliance and oversight of the charity, induding
independent examination lees. accounts preparation costs and trustee meeling expenses.
Governanc? ¢r)$ts artr present￿ as a separate ¢omwrwit of eX￿nd11yre in th¥ Ststemtrnl of Flnan¢lal
Activities.
1.5 Intonglblg Ilxod 0¥ty9ts oth•r than goodwlll
Amortisation is recognised so as to write off the cosl or valualTh ol assets less their residual values over their
U8elLJI lives on the following bases..
Websile
10% on reducing balance
1.6 Tanglbl• flx•d a8S•ts
Depreciation is recognised so as to writg off the ￿$t or valuation o18s$0ts le$$ their widual valutrs over their
useful lives on the fdlowing basès..
P18nt and equiprnenl
Cornpulers
25% on reduung balanee
33% on ￿￿¢ing balance
1.7 Flxed asset Investments
Lisled inv85tments are inits'ally recognised at cosl 8nd subsequ8nUy m8a5ured at fair value 8t the b818nc8
sheet date, based on quoted rna￿et prices. Changes in fair value are recognised as gains or losses on
investments in the Statement of Finanaal Aclmbes. Investment income is recognised when receivable.
1.8 Cash and cash equivalents
Cash and cash equivalents include cash in hand. deposits held at call vAth banks. olher 5hort-term liquid
inv8Stments wth original maturities of three rnonths or 18SS, 8nd bank overdr8fts. B8nk overdrafts ar8 shown
thin borrowings in current Iiabilitie5.
19-

THE CANCER TREATMENT AND RESEARCH TRUST
NOTES TO THE FINANCIAL STATEMENTS {CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
Aeeounting pollelès
IContlnu•d)
1.9 Financial instruments
The chanty has elected to apply the provisions of sect￿ 11 'Basic Financial Instruments, and Section 12
'Other Financial Instruments Issues. ol FRS 102 lo all ol its financial instnJments.
Financial instruments recognised in the tharitys balance sheel when the ch8rity be(x)mes party to the
contractual prowsions of the InstnJm8nt.
Financial assets and liabilities offsel. wth the nel amounts presented in the financial statements, when
there is a legally enforceable right to set off the recognised amounts and there is an intention to setue on a net
basis or to realise the asset and setue the liability simultaneously.
Baslc Ilnanclal assets
Basic financial assets. which indude debtors and cash and bank balances. are initially rneasured at
lrans8cts.on price including transaction costs and are subsequenuy carried at amortised c05t Using the effective
interest method unless the arrangement constitutes a finantyng transaction, where the Irarisactitsn is
mèasurèd al thè prèseni valuè ol the future recèipts discount8d at 8 markèt ratè of interèst. Fin8na81 assèts
classified as receivable within one year arè Th)t am0￿"S￿d.
Basic flnancial liabillties
Basic financial Iiabililies. induding uaditots and bank ￿an$ arè Initlally r•cognlsad at transaction prfc• unlass
the arrangement conslilules a financing Iransaclion. where the debt instrument is measured al the present
value ol the future payments discounted at a maikel late ol interest. Financial liabilitses classified as payable
thin one year 8re not amortised.
Tradg cr8ditors arè obligabon$ lo p8y go￿￿$ LY s¢rvieè$ thal hovè bgèn affjuirgd in tho ordinary cours¥ of
operations from supplièrs. Amounts payable arè dasstfied as etsrrènt liabilitiès if paymanl is duè within on6
year or less. If not, they a￿ presented as non-currenl liabilities. Trade creditors are recognised initially at
transacts'on price and subsequenlly measured al amortised cost using the effeclive interest rnethod.
1.10 Taxatlon
The charity is exempt from corporation lax on ils chariiable activi1￿.
1.11 Employee b¢nellts
The cost of any unused holiday enlitlement is recognised in the wiod in which the employee's services are
received.
Terrnin8lion beneffts are re(￿gnIsed immeili81ety 8s an expense when the ch8rity is demonstrably cornmilled
to tamiinatè thè èmploymènt ol an émployaè or to provid8 tèmination bènéfts.
1.12 P•nsion costs and oth•r post*•tir•m•nt b•n•ffts
Payrnents to defineil Ixjntribution reb'refflenl benefft sthemes are charged as an expense as they fall due.
1.13 Fund aeeounting
Unrestricted fvnds can be used in ac(x)rdance with the charilable ob￿l￿e5 * the discretion of the truste85.
Restricted funds can only be used for particular ￿$trIcted purposes wlhin the objects of the charity.
Restrictions arise when speufied by the donor OT when fvnds are raised for particular restricted purposes.
Further explanation of the nature and purwjse of each fvnd is indtKled in the notes to the financkgl
staternents.

THE CANCER TREATMENT AND RESEARCH TRUST
NOTES TO THE FINANCIAL STATEMENTS {CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
Aeeounting pollelès
IContlnu•d)
1.14 Current asset in¥eslments
Current asset investments comprise fun¢Js held in short-tem bank deposit accounts lor the purpose of
generating investment income. rather than meeting immediate operating wuirements. These deposits are
measured al the amount deposiled. together wilh any accrued interest receivable where applicable.
Income from donation and legacies
Unr•strlded R•strfded
fund$
fund$
2025
2025
Total Unrèstrlcted Rèstrlcted
fund$
fund$
2024
2024
Total
2025
2024
Donations and gilts
289.876
11.015
300,891
384.379
100,182
484.561
Incom• from Inv•stm•nt
Unr•8trlctod Unrfrstrlcted
funds
funds
2025
2024
Income frorn listed investments
Int8r8St r8cèivabl¥
496
24,384
646
16.944
24,880
17.590
Exp•ndltur• on r•lslng funds
Unre8trfcted Unrestrlcted
funds
funds
2025
2024
Fundraising and publicity
Seeking donations. grants and legacies
7,643
5,108
21

THE CANCER TREATMENT AND RESEARCH TRUST
NOTES TO THE FINANCIAL STATEMENTS {CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
Expenditure on charitable activities
UF
RF
CharTrtable Charltable
expenditure expenditure
2025
2025
Total
Total
2025
2024
DSr•ct costs
Research expenses and lab fees
Conference and MeetiThJ
2.956
207,520
210,476
2,004
83,637
2.134
207,520
212,460
85.771
Trust•es
N¢ irustees ts¢•l￿d remuntrralion for Ihtrir services.
Employ•••
The average monthly number ol employees during the year was..
2025
Number
2024
Number
There were no employees whose annual remuneration was more than £60,rx)o.

THE CANCER TREATMENT AND RESEARCH TRUST
NOTES TO THE FINANCIAL STATEMENTS {CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
Support and governance costs
Support and govemance eosts represent expenditure vA)ich is not direclly attn"butable to a specific charitable
activity but is necessary Ihe charity's overall operations and statutory compliance.
Unr•strSded Unr•strlct•d
funds
funds
2025
2024
Subscription
Travèl and subsistance
Wages
Social security costs
Pension
Insurance
S18ff training
Telephone
Postag8 and stationary
Advertising
Computer expenses
Daprèciation - pl8nt and machinery
Depreciation - cornputer equipment
Amortisalion Wèbsit•
Bank ch8rges
Entertainment
Accountancy 188s
5,005
295
26.845
3.252
70
25.751
329
328
691
339
703
274
72
277
4,215
2,300
36
446
416
4,232
417
17,836
72
319
361
1.905
47
692
168
2,640
326
14,372
63,708
51,323
Support eosts repr8s¢nl the gtrneral admini$tr8tive expenditure Of Ihtr chanty. These ¢o$t$ ar8 allocated to an
èxpenditur8 h88ding wherg the aclivity dIT￿Y banèfils (rnm such 4x￿nditurè,. whar8 allocation is not
possible, the costs are shown vthhin supwl costs.
Galns and losses on Investments
Unre$tri￿ed Unrestri¢ted
funds
funds
2025
2024
Gainslllossesl arising on..
Rgvaluation of inv9Stments
51,834
The gain of £51,834 represents Ihe revaluation of the charitys listed sharehdding to its quoted market value
at 31 D8C8tnb8r 2025. The inv85tsnent was pr8viously rarri8d at historical cost 8nd th8 gain ther8ft>r8 includes
appreciation arising in earfier accountsng periods.
10 Taxatlon
The charity is exempt from tsxation on its acti¥￿e5 because 811 ts in(x>rne is applied for charitable purposes.
-23-

THE CANCER TREATMENT AND RESEARCH TRUST
NOTES TO THE FINANCIAL STATEMENTS {CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
11 Intangible fixed assets
Web¥lt•
Cost
At 1 January 2025
Additions
1.858
4,200
At 31 Daeèmbèr 2025
6.058
Amortlsatlon and Impalmi•nt
At 1 January 2025
Amortisation charged for the year
353
416
At 31 Decernber 2025
769
C•rrylng amount
At 31 December 2025
5.289
At 31 Decernber 2024
1.505
12 Tanglble fixed ass•ls
Pl4nt and
¢qulpffl•n¢
Comput•r•
Total
Cost
At 1 January 2025
338
5,495
5,833
At 31 December 2025
338
S.495
5,833
Oepreclatlon and Impalmi•nt
At 1 January 2025
Oeprecia¢ion charged in Ihe year
194
36
4,144
446
4,338
482
At 31 Decernber 2025
230
4,590
4,820
Carrying amount
At 31 December 2025
108
1.013
At 31 Decernber 2024
144
1,350
1,494
-24-

THE CANCER TREATMENT AND RESEARCH TRUST
NOTES TO THE FINANCIAL STATEMENTS {CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
13 Fixed asset investments
Listed
invo$tmgnt$
Cost or valuation
At 1 January 2025
Fair value adjustments
6.469
51.834
At 31 December 2025
58.303
Carrying amount
At 31 December 2025
58.303
At 31 December 2024
6.469
14 O•btors
2025
2024
Amounts falling du• wthin on• y•ar:
Trade debtors
Other debtors
Prepaymènts ¥nd a¢cru8d incom
1.861
21,192
9.744
1.721
8,553
32,797
10.274
15 Currént a88•t Inv•stm•nts
2025
2024
Bank deposit
765.979
The charity holds £765,97912024= £nill in bank deposit aoxunts. These funds re￿sent surplus cash pla￿d
on deposit during the year to generaie investmenl in￿rne pending their application iowards future chariiable
activities.
16 Cr•dltors'. amounts falllng du• wrthln on• y•ar
2025
2024
Other taxation and social security
Trade creditors
Other creditors
Accruals and deferred incA)me
80
28,667
20,124
57
52.848
37,271
73,029
66,018
-25-

000 000 Voo
*0 000 00(ry ¢J)r
000 OON
¢J) N (
0￿￿￿)￿00
8 8X 8
O W)
¢ry m C
io
ggg ggg g=-g-
C) > O
q> q> J<
> (LW > (o (LE o u￿￿
CLZ(rJiZ(r(rJ_Ji)fLott EEwrLfiSJufLO<

THE CANCER TREATMENT AND RESEARCH TRUST
NOTES TO THE FINANCIAL STATEMENTS {CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
19 Analysis of net assets between funds
Unrestricted
funds
2025
Restricted
funds
2025
Total
2025
At 31 December 2025-
Intangible fixed assets
Tangible assets
Investrnents
Current assetsllliabilitiesl
5.289
1,013
58,303
1.221.038
5.289
1.013
58,303
1.574.589
353.551
1.285.643
353,551
1.639,194
Unr•8trletèd
funds
2024
Rè8trlet•d
funds
2024
Total
2024
At 31 Decomb•r 2024:
Intangiblè lixod ass$l$
Tangible assets
Investments
Current 8ssetsllli8bililitr$l
1.505
1,494
6.469
1.194,710
1.505
1,494
6.469
1.535,952
341,242
1,204,178
341,242
1,54S,420
20 R•lated party tran8actlons
The charity 18 required to disdlxe m•ieri81 related party tr8ns8C1￿ns under Ihe Ch8ri1ies SORP IFRS 1021.
During thè y•ar'.
No trustee received remuneration from the charity.
Transactions wlh (Tuslees a￿ disdosed in note 6.
No Iwslees or persons ¢onr￿cled wilh Ihern had any personal interesl in any ￿ntraCtS or
Iran53¢tion5 enlered into by the charity.
No other r6latail party transactic￿$ wuire disdosum.